|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/506 | |
| A61P 27/02 | |||
| A61K 31/55 | |||
| A61K 31/7052 | |||
| A61K 39/395 |
| (11) | Patento numeris | 2329821 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10170798.2 |
| Europos patento paraiškos padavimo data | 2006-11-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-06-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2012-08-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 740478 P | 2005-11-29 | US |
| (72) |
Brigandi, Richard Anthony, US
Levick, Mark, US
Miller, William Henry, US
|
| (73) |
GlaxoSmithKline LLC,
One Franklin Plaza 200 North 16th Street, Philadelphia, PA 19102,
US
|
| (54) | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |